Defiance Daily Target 2X Long HIMS ETF

Hims & Hers Health Inc. Collaborates with GRAIL to Offer Multi-Cancer Early Detection Test

Kelly Services-B

Liminatus Pharma

Pro Ultrshrt Silver

UTime

GraniteShares 2x Short MSTR Daily ETF

Defiance Daily Target 2X Short MSTR ETF

T-REX 2X Inverse MSTR Daily Target ETF

Defiance Daily Target 2X Short QBTS ETF

TruGolf

C3is

NVOX

HIMY

HIMZ

HIMS

Telemedicine company Hims launched a generic version, priced at $99 per month, significantly lower than the brand-name drug at $149. Novo Nordisk accused it of "illegal compounding" and threatened to sue, claiming the generic lacks proprietary protection technology and cannot be effectively absorbed. Hims argued that it uses a different formula. As a result, Novo Nordisk's stock price plummeted over 8%

- Novo Nordisk faced an unexpected market challenge with the launch of Hims & Hers Health’s generic version of its obesity drug Wegovy, priced significantly lower.  
- The introduction of the generic version sparked debates over drug patent protection and regulatory frameworks, with Novo Nordisk expressing intentions to protect its intellectual property legally.  
- As a result of this news, Novo Nordisk's stock fell over 8%, while competitors like Eli Lilly also experienced declines, indicating heightened investor concerns regarding market position and growth expectations.

Wallstreetcn

Novo Nordisk AS

Defiance Daily Target 2X Long NVO ETF

Defiance Leveraged Long +Income HIMS ETF

Hims & Hers Health

Novo Nordisk plummeted 8%, as the new weight loss pill faced "knockoffs" right after its launch, with telemedicine company Hims introducing a $49 generic version

Pathway Capital Management LP acquired 119,279 shares of Hims & Hers Health, Inc. (NYSE:HIMS) valued at approximately $6.77 million, making it the largest position in their portfolio. Other institutional investors also increased their stakes in Hims & Hers Health. The company reported a revenue of $598.98 million for the last quarter, missing EPS estimates but showing a 49.2% year-over-year revenue growth. Hims & Hers Health's board approved a $250 million share repurchase program, indicating confidence in the stock's value.

Market Beat

SPDR S&P Health

Health Care Select Sector SPDR

VG Health

iShares US Healthcare Providers

iShares Global Healthcare

119,279 Shares in Hims & Hers Health, Inc. $HIMS Purchased by Pathway Capital Management LP

Oluyemi Okupe, CFO of Hims & Hers Health Inc., reported the disposal of common shares of the company. The full filing is available through the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice. Hims & Hers Health Inc. is responsible for the original content published via EDGAR on February 04, 2026.

Reuters

Hims & Hers Health CFO Oluyemi Okupe Reports Disposal of Common Shares

INSTANT VIEW-Hims and Hers Health's compounded Wegovy pill offering fuels market jitters

marketscreener

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

SPDR S&P Health Equip

iShares Biotechnology ETF

ALPS Medical Breakthrough

iShares US Medical Devices

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares US Pharma

Invesco Biotechnology & Genome ETF

INSTANT VIEW-Hims and Hers Health's compounded Wegovy pill offering fuels market jitters

Hims & Hers attacks the rich in its Super Bowl ad — including a Jeff Bezos lookalike

businessinsider

Hims & Hers attacks the rich in its Super Bowl ad — including a Jeff Bezos lookalike

VKTX

Weight loss drug concept stocks generally fell, Viking Therapeutics dropped 11.06%, Scholar Rock fell 9.91%, Novo Nordisk ADR fell 8.16%, Eli Lilly fell 7.79%, Hims & Hers fell 3.77%

Viking Therap

Eli Lilly

Peak Retirement Planning Inc. has invested $2.84 million in Hims & Hers Health, acquiring 50,096 shares, making it the 22nd largest position in its portfolio. Other institutional investors have also increased their stakes. Hims & Hers Health's stock is currently down 2.4%, with a market cap of $6.02 billion. The company reported earnings of $0.06 per share, missing estimates, but revenue increased by 49.2% year-over-year. Hims & Hers has initiated a $250 million stock buyback program, indicating management believes shares are undervalued.

Peak Retirement Planning Inc. Invests $2.84 Million in Hims & Hers Health, Inc. $HIMS

Novo Nordisk issued a statement accusing Hims & Hers of "illegal, large-scale formulation and deceptive advertising," stating that its business practices may pose safety risks. Novo Nordisk emphasized that the company only produces the weight loss drug Wegovy, which is approved by the U.S. FDA

Novo Nordisk's stock price fell more than 7% in pre-market trading on Thursday, as the market focused on its competitor Hims & Hers Health launching a new weight loss generic drug at a lower price. Hims & Hers Health's subscription plan starts at just $49 per month, while Novo Nordisk's branded weight loss medication starts at $149 per month

AASTOCKS

Novo Nordisk fell more than 7% in pre-market trading after reports that competitor Hims & Hers is launching a new low-cost weight loss generic drug

Hims & Hers is launching a new Super Bowl ad addressing healthcare affordability, shifting focus from Big Pharma to the privatized U.S. healthcare system. The ad, narrated by rapper Common, highlights the disparity in healthcare access between the wealthy and the general public, emphasizing that the rich have better healthcare options. Hims & Hers aims to democratize access to personalized care, challenging the status quo and advocating for a system that benefits everyone, not just the affluent. The company anticipates controversy similar to last year's ad, as it confronts uncomfortable truths about healthcare inequality.

Fiercepharma

Hims uses new Super Bowl ad to tackle healthcare affordability

Hims & Hers Health Inc. has partnered with GRAIL, Inc. to provide access to the Galleri® Multi-Cancer Early Detection test through its digital platform. This collaboration allows customers to utilize a blood test that screens for over 50 types of cancer before symptoms arise, promoting proactive health management. The initiative aims to enhance accessibility to cancer detection and empower individuals in their health journey.

iShares Genomics Immunology and Healthcare ETF

Hims & Hers Teams Up With GRAIL to Offer Multi-Cancer Early Detection Test

Investors are taking a bearish stance on Hims & Hers Health (NYSE:HIMS), with 14 unusual options trades detected. The sentiment is split, with 35% bullish and 50% bearish. Significant trades include 2 puts totaling $53,536 and 12 calls totaling $530,252. The price range targeted by large investors is between $30.0 and $100.0. Currently, HIMS is trading at $30.17, down 2.94%, with a consensus target price of $33.0 from market experts. The next earnings report is due in 27 days.

benzinga_article

Looking At Hims & Hers Health's Recent Unusual Options Activity

Novo Nordisk ADR fell 6.3% in pre-market trading, reports that "value pharmaceutical supplier" Hims & Hers offers a $49 Wegovy generic

Hims & Hers Health shares are trending after launching the Multi-Cancer Test, which screens for over 50 types of cancer. The test, offered in partnership with GRAIL Inc., is designed for annual use and aims to enhance early detection. Despite the positive launch, HIMS stock is facing mixed momentum, trading significantly below its moving averages and showing bearish indicators. The Benzinga Edge rankings reveal strong growth potential but caution investors due to weak value and bearish momentum. Currently, Hims shares are trading at $25.29, down 0.94%.

Hims & Hers Shares In The Spotlight After Launching Multi-Cancer Test

The "affordable weight loss drug" supplier Hims & Hers fell 1.4%, having risen as much as 14% earlier in the day

Defiance Daily Target 2X Long HIMS ETF(HIMZ.US)

Novo Nordisk plummeted 8%, as the new weight loss pill faced "knockoffs" right after its launch, with telemedicine company Hims introducing a $49 generic version

119,279 Shares in Hims & Hers Health, Inc. $HIMS Purchased by Pathway Capital Management LP

Hims & Hers Health CFO Oluyemi Okupe Reports Disposal of Common Shares

INSTANT VIEW-Hims and Hers Health's compounded Wegovy pill offering fuels market jitters

Hims & Hers attacks the rich in its Super Bowl ad — including a Jeff Bezos lookalike